STAT6 siRNA Matrix-Loaded Gelatin Nanocarriers: Formulation, Characterization, and Ex Vivo Proof of Concept Using Adenocarcinoma Cells

The clinical utility of siRNA therapy has been hampered due to poor cell penetration, nonspecific effects, rapid degradation, and short half-life. We herewith proposed the formulation development of STAT6 siRNA (S6S) nanotherapeutic agent by encapsulating them within gelatin nanocarriers (GNC). The...

Descripción completa

Detalles Bibliográficos
Autores principales: Youngren, Susanne R., Tekade, Rakesh K., Gustilo, Brianne, Hoffmann, Peter R., Chougule, Mahavir B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806510/
https://www.ncbi.nlm.nih.gov/pubmed/24191252
http://dx.doi.org/10.1155/2013/858946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806510/
https://www.ncbi.nlm.nih.gov/pubmed/24191252
http://dx.doi.org/10.1155/2013/858946

Ejemplares similares